Diversity of glpK Gene and Its Effect on Drug Sensitivity in Mycobacterium bovis
Yuhui Dong,Xichao Ou,Chunfa Liu,Weixing Fan,Yanlin Zhao,Xiangmei Zhou
DOI: https://doi.org/10.2147/IDR.S346724
2022-04-01
Infection and Drug Resistance
Abstract:Yuhui Dong, 1 Xichao Ou, 2 Chunfa Liu, 2 Weixing Fan, 3 Yanlin Zhao, 2 Xiangmei Zhou 1 1 Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, National Animal Transmissible Spongiform Encephalopathy Laboratory, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, People's Republic of China; 2 National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China; 3 National Reference Laboratory for Animal Tuberculosis, China Animal Health and Epidemiology Center, Qingdao, 266032, People's Republic of China Correspondence: Xiangmei Zhou, Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, National Animal Transmissible Spongiform Encephalopathy Laboratory, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, People's Republic of China, Email Background: Glycerol kinase ( glpK ) is essential for the first step of glycerol catabolism in Mycobacterium tuberculosis . However, Mycobacterium bovis has been known to grow poorly in glycerol media because of a base insertion in the glpK gene. Methods: We analyzed the glpK gene sequences of 60 clinical M. bovis isolates, and determined the minimum inhibitory concentration of 14 drugs by microdilution method to evaluate the effect of frameshift mutations on drug sensitivity. The effect of M. bovis growth rate on its drug sensitivity was investigated using bacteria grown on glycerol or pyruvate. Results: A total of 44 (73.33%) clinical M. bovis isolates have frameshift mutations in a homopolymeric tract of 7 cytosines in the glpK gene. 15.00% M. bovis isolates showed phenotypic drug resistance. Glycerol metabolism-deficient M. bovis showed reduced susceptibility to 9 out of 14 tested drugs. Mutations in the glpK gene can lead to impaired growth in glycerol-based media, while the minimal inhibitory concentration values of slow-growing M. bovis were higher. Conclusion: Mutations in the glpK gene can lead to slowed growth and reduced susceptibility to drugs in M. bovis , which may contribute to the emergence of drug-resistant M. bovis and pose a threat to human health owing to the zoonotic capacity of M. bovis . Keywords: Mycobacterium bovis , tuberculosis, glpK , drug resistance Tuberculosis (TB), a communicable disease, ranks as the second leading cause of death from a single infectious agent, after COVID-19 in 2020, with roughly a quarter of the world's population infected with Mycobacterium tuberculosis . 1 Since 1990, TB mortality has decreased; nevertheless, the rise of multidrug-resistant (MDR) and extremely drug-resistant (XDR) strains of M. tuberculosis represents a serious public health threat. 1–3 Unlike drug-sensitive TB, which can be treated by 6 months of chemotherapy with the current four-drug frontline regimen, MDR-TB requires at least 18 to 24 months of therapy with four to six drugs, including fluoroquinolone and one injectable agent. 2,4,5 The M. tuberculosis complex is a group of closely genetically related yet phenotypically diverse organisms. 6 A range of in vitro characteristics can be used to distinguish the members of the complex; for example, unlike M. tuberculosis, M. bovis is unable to utilise glycerol as its sole carbon source. 7 M. bovis primarily infects cattle, but can also infect a wide range of species, including humans. 8 The genomes of M. bovis and M. tuberculosis are more than 99.95% identical, and the symptoms of human disease caused by M. bovis are similar to those of disease caused by M. tuberculosis . 9,10 Treatment of disease caused by M. bovis usually includes rifampicin, isoniazid, and ethambutol. 11 Due to the exclusion of pyrazinamide, since all strains of M. bovis are resistant to it, treatment duration is generally extended to 9 months. 12 There have been some reports of infections caused by MDR M. bovis , including both sporadic cases and transcontinental outbreaks. 13–17 The 2020 WHO global tuberculosis report estimated that there were 140,000 new human cases of zoonotic tuberculosis caused by M. bovis globally in 2019. 3 The use of culture media such as glycerol, that inhibit M. bovis growth, has led to the number of human cases of M. bovis infection being underestimated -Abstract Truncated-
pharmacology & pharmacy,infectious diseases